Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology - 1 Jan 2015

Karaköse Süleyman, Oruç Nevin, Zengin Melia, Akarca Ulus Salih, Ersöz Galip

Abstract excerpt

BACKGROUND/AIMS: The diagnosis of an underlying myeloproliferative neoplasm (MPN) is often problematic in patients with Budd Chiari syndrome (BCS) or portal vein thrombosis (PVT). This study aimed to assess the diagnostic value of the JAK2 gene V617F gain-of-function mutation for MPN in splanchnic vein thrombosis patients. MATERIALS AND METHODS: One hundred eleven patients (80 with PVT, 27 with BCS, and 4 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Budd-Chiari Syndrome
Share to Chronic Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Genetic Testing

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Portal Vein

Share to Venous Thrombosis

Source

Identifiers

PMID: 25698270
DOI: 10.5152/tjg.2015.5738

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.PMID 25698270Read ↗

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.Semantic proximity Read ↗

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.Semantic proximity Read ↗

Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.Semantic proximity Read ↗

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.Semantic proximity Read ↗

JAK2V617F mutation in patients with splanchnic vein thrombosis.Semantic proximity Read ↗

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.Semantic proximity Read ↗

Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.Semantic proximity Read ↗

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Semantic proximity Read ↗

Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.Semantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.